BioArctic: A new treatment paradigm taking shape - Redeye

Redeye's view continues to be that BioArctic's drug candidate lecanemab has a high likelihood of approval and the best clinical profile and dataset in the amyloid-beta space. We maintain our valuation and expect a commercial breakthrough after a potential full approval in the US once results from Clarity AD become available this fall.

Länk till analysen i sin helhet: https://www.redeye.se/research/837521/bioarctic-a-new-treatment-paradigm-taking-shape?utm_source=finwire&utm_medium=RSS